Eton Pharmaceuticals, Inc. — Director's Dealing 2022

Feb 28, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Eton Pharmaceuticals, Inc. (ETON)
CIK: 0001710340
Period of Report: 2022-02-07

Reporting Person: MAIER PAUL V (Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-07	Stock Option(Right to buy)	$3.78	A	50000	Acquired	2032-02-07	Common Stock (50000)	Direct

Footnotes

F1: The shares subject to the option shall vest on a quarterly basis over 12 months from the date of grant until fully vested and exercisable on February 7, 2023.